748P Prognostic factors related to post-platinum atezolizumab for relapsed metastatic urothelial cancer (mUC) from the SAUL study.
Saved in:
| Title: | 748P Prognostic factors related to post-platinum atezolizumab for relapsed metastatic urothelial cancer (mUC) from the SAUL study. |
|---|---|
| Authors: | Bamias, A.1 (AUTHOR), Merseburger, A.2 (AUTHOR), Loriot, Y.3 (AUTHOR), James, N.4 (AUTHOR), Choy, E.5 (AUTHOR), Castellano Gauna, D.6 (AUTHOR), Lopez-Rios, F.7 (AUTHOR), Calabro, F.8 (AUTHOR), Kramer, M.W.9 (AUTHOR), de Velasco, G.6 (AUTHOR), Zakopoulou, R.10 (AUTHOR), Tzannis, K.1 (AUTHOR), Sternberg, C.N.11 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS581-S581. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2020.08.820 |
